Metabolic and cardiovascular effects of androgen deprivation therapy
Authors:
- Payam HakimianPHPayam Hakimian
- Michael BluteMBMichael Blute
Open Access
- 21 November 2008
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 102 (11) , 1509-1514
Abstract
Prostate cancer is the most common gender‐specific malignancy in men in the USA. Androgen‐deprivation therapy (ADT) is commonly used in the treatment of metastatic or recurrent prostate cancer. The use of ADT is increasing with the advocacy of adjuvant and neoadjuvant ADT for treating asymptomatic patients with locally advanced prostate cancer. Although the use of ADT has resulted in improved survival in men with advanced prostate cancer, ADT, with its resulting severe hypogonadism, causes profound metabolic side‐effects. We comprehensively reviewed previous reports using Medline searches of English‐language literature (1950 to the present), with the keywords ‘hypogonadism’, ‘testosterone’, ‘androgen deprivation therapy’, ‘hormonal treatment’, ‘prostate cancer’, ‘diabetes’, ‘metabolic syndrome’, and ‘cardiovascular disease’. Men with prostate cancer who undergo long‐term ADT are at greater risk of developing dyslipidaemia, insulin resistance, hyperglycaemia and metabolic syndrome. These metabolic and physiological changes are a direct result of the induced severe hypogonadism and might predispose patients to a greater risk of cardiovascular morbidity and mortality. There is a need for prospective studies aimed and designed to investigate the metabolic and cardiovascular adverse effects of ADT, and assess the benefit/risk ratio, especially in special populations such as diabetics.Keywords
This publication has 56 references indexed in Scilit:
- Low Serum Testosterone and Mortality in Older MenThe Journal of Clinical Endocrinology & Metabolism, 2008
- Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancerBJU International, 2007
- Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Oncology, 2006
- The Effect of Androgen Deprivation Therapy on Fasting Serum Lipid and Glucose ParametersJournal of Urology, 2006
- Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation TherapyJournal of Clinical Oncology, 2006
- Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen‐deprivation therapyCancer, 2005
- Management of Bone Loss in Men With Prostate CancerJournal of Urology, 2003
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Immediate Hormonal Therapy Compared with Observation after Radical Prostatectomy and Pelvic Lymphadenectomy in Men with Node-Positive Prostate CancerNew England Journal of Medicine, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999